Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer - A single center randomized study

Simple item page
dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.buuauthorBaran, İbrahim
dc.contributor.buuauthorCoşkun, H. Hakan
dc.contributor.buuauthorZarifoğlu, Mehmet
dc.contributor.buuauthorTuran, Ömer Faruk
dc.contributor.buuauthorKurt, Ender
dc.contributor.buuauthorDemiray, Mutlu
dc.contributor.buuauthorGönüllü, Güzin
dc.contributor.buuauthorManavoğlu, Osman
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Medikal Onkoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Kulak Burun ve Boğaz Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-9732-5340tr_TR
dc.contributor.orcid0000-0003-2501-3097tr_TR
dc.contributor.researcheridAAJ-1027-2021tr_TR
dc.contributor.researcheridM-8060-2019tr_TR
dc.contributor.scopusid55881548500tr_TR
dc.contributor.scopusid6603942124tr_TR
dc.contributor.scopusid35572557400tr_TR
dc.contributor.scopusid13610800100tr_TR
dc.contributor.scopusid6603411305tr_TR
dc.contributor.scopusid23037113500tr_TR
dc.contributor.scopusid7006207332tr_TR
dc.contributor.scopusid6603631569tr_TR
dc.contributor.scopusid6506410014tr_TR
dc.contributor.scopusid6602587152tr_TR
dc.date.accessioned2022-03-16T10:55:20Z
dc.date.available2022-03-16T10:55:20Z
dc.date.issued2003
dc.description.abstractAim: In this study we determined the protective role of amifostine against the side effects of the combination of paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). Patients and Methods: Chemo-naive patients with NSCLC were eligible. Thirty-eight patients were randomized to receive paclitaxel 175 mg/m(2) and carboplatin AUC = 6 with amifostine 9 10 mg/m(2) (group 13) or chemotherapy alone (group A). The occurrences of hematologic, neurologic, cardiologic toxicities, and ototoxicity were evaluated. Results: All patients completed the six scheduled cycles of therapy. A total of H 4 cycles of chemotherapy was given in both groups. Neutropenia grade 3-4 was observed in 11 cycles (9.6%) in group A and 19 cycles (16.6%) in group B (p = 0.16). Paresthesia grade 1 or 2 was observed in 18 of 19 patients of group A and in 8 of 19 patients of group B, following the sixth cycle of chemotherapy (p = 0.018). Two patients of group B and nine patients of group A suffered from sensory motor impairment grade 2 (p = 0.029). There was no clinical evidence in any patient for deterioration in cardiac function. Asymptomatic and transient sinus bradycardia or ventricular premature beats developed in four patients. None of the patients reported vertigo, tinnitus, or hearing loss. Conclusion: The addition of the amifostine to the combination of paclitaxel and carboplatin may prevent or reduce the incidence of neurotoxicity in the treatment of NSCLC. Amifostine does not appear to have a preventive role in neutropenia.en_US
dc.identifier.citationKanat, Ö. vd. (2003). “Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer - A single center randomized study”. Medical Oncology, 20(3), 237-245.en_US
dc.identifier.endpage245tr_TR
dc.identifier.issn1357-0560
dc.identifier.issue3tr_TR
dc.identifier.pubmed14514973tr_TR
dc.identifier.scopus2-s2.0-10744221906tr_TR
dc.identifier.startpage237tr_TR
dc.identifier.urihttps://doi.org/10.1385/MO:20:3:237
dc.identifier.urihttps://link.springer.com/article/10.1385/MO:20:3:237
dc.identifier.urihttp://hdl.handle.net/11452/25084
dc.identifier.volume20tr_TR
dc.identifier.wos000185585900005tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherHumana Pressen_US
dc.relation.journalMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectAmifostineen_US
dc.subjectPaclitaxelen_US
dc.subjectCarboplatinen_US
dc.subjectCisplatin plus vinorelbineen_US
dc.subjectPhase-IIen_US
dc.subjectTrialen_US
dc.subjectCombinationen_US
dc.subjectInfusionen_US
dc.subject1-houren_US
dc.subjectDamageen_US
dc.subjectAgenten_US
dc.subjectHeaden_US
dc.subject.emtreeAmifostineen_US
dc.subject.emtreeAntiemetic agenten_US
dc.subject.emtreeCarboplatinen_US
dc.subject.emtreeDexamethasoneen_US
dc.subject.emtreeDiphenhydramineen_US
dc.subject.emtreePaclitaxelen_US
dc.subject.emtreeRanitidineen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAnemiaen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBlood toxicityen_US
dc.subject.emtreeCancer chemotherapyen_US
dc.subject.emtreeCardiotoxicityen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDeteriorationen_US
dc.subject.emtreeDisease courseen_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeDrug hypersensitivityen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHearing lossen_US
dc.subject.emtreeHeart functionen_US
dc.subject.emtreeHeart ventricle extrasystoleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHypotensionen_US
dc.subject.emtreeLung non small cell canceren_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMotor dysfunctionen_US
dc.subject.emtreeNeurotoxicityen_US
dc.subject.emtreeNeutropeniaen_US
dc.subject.emtreeOtotoxicityen_US
dc.subject.emtreeParesthesiaen_US
dc.subject.emtreePatient selectionen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProtectionen_US
dc.subject.emtreeRandomizationen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeSensory dysfunctionen_US
dc.subject.emtreeSinus bradycardiaen_US
dc.subject.emtreeThrombocytopeniaen_US
dc.subject.emtreeTinnitusen_US
dc.subject.emtreeToxicityen_US
dc.subject.emtreeVertigoen_US
dc.subject.emtreeVomitingen_US
dc.subject.meshAmifostineen_US
dc.subject.meshAntineoplastic combined chemotherapy protocolsen_US
dc.subject.meshCarboplatinen_US
dc.subject.meshCarcinoma, non-small-cell lungen_US
dc.subject.meshCytoprotectionen_US
dc.subject.meshFemaleen_US
dc.subject.meshHeart diseasesen_US
dc.subject.meshHematologic diseasesen_US
dc.subject.meshHumansen_US
dc.subject.meshLung neoplasmsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshNervous system diseasesen_US
dc.subject.meshPaclitaxelen_US
dc.subject.meshProspective studiesen_US
dc.subject.meshProtective agentsen_US
dc.subject.scopusPemetrexed; Non-Small Cell Lung Carcinoma; Carboplatinen_US
dc.subject.wosOncologyen_US
dc.titleProtective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer - A single center randomized studyen_US
dc.typeArticle
dc.wos.quartileQ4en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus